Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in aandelen #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Aandeelprijs
$0.00185055
Marktkapitalisatie
$48.29K
Verandering (1 dag)
-3.55%
Verandering (1 jaar)
30.31%
Land
GB
Handel Nuformix plc (NFX)

Categorie

Winst voor Nuformix plc (NFX)
Winst in Mar 2026 TTM: $-857.89K
Volgens de meest recente financiële verslagen van Nuformix plc bedraagt de huidige winst van het bedrijf $-857.89K. In 2024 behaalde het bedrijf een winst van $-4.88M, een daling ten opzichte van de winst van 2023, die $-754.56K bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Nuformix plc van 2014 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B -614,967.33%
US
$-3.09B 359,735.34%
US
$-4.02B 468,046.88%
AU
$1.95B -227,477.01%
NL
- -
CH